The Government has produced a short guidance document to help the life science sector prepare for, and navigate through, the planned Brexit implementation period.

The period, yet to be legally confirmed, is set to last from the UK’s formal departure on 29 March 2019 to 31 December 2020. The guidance addresses changes taking place before, during and after the period, as well as highlighting areas like the Clinical Trials Regulation (CTR).

Updates are given on the MHRA’s preparatory work to transfer its active projects to the EMA, the loss of UK voting rights in decision-making around medicines during the period, and the commitment to offer a competitive service for clinical trial assessment should the CTR not be implemented within the expected timeframe.

Although the guidance remains subject to the Withdrawal Agreement being legally agreed, the Government has pledged to act in the best interests of patients through continued close cooperation between the EU and the UK.